X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
P/E ratio for X4 Pharmaceuticals, Inc. (XFOR)
P/E ratio as of 2023: -1.47
According to X4 Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.47. At the end of 2022 the company had a P/E ratio of -0.67.
P/E ratio history for X4 Pharmaceuticals, Inc. from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.47 |
| 2022 | -0.67 |
| 2021 | -0.66 |
| 2020 | -2.08 |
| 2019 | -2.18 |
| 2018 | -0.15 |
| 2017 | -0.78 |
| 2016 | -3.40 |
| 2015 | -5.91 |